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Abstract
Purpose Prostate cancer management strategies are
evolving with increased understanding of the disease.
Specifically, there is emerging evidence that ‘‘low-risk’’
cancer is best treated with observation, while localized
‘‘high-risk’’ cancer requires aggressive curative therapy. In
this study, we evaluated trends in management of prostate
cancer in New Hampshire to determine adherence to evi-
dence-based practice.
Methods From the New Hampshire State Cancer Reg-
istry, cases of clinically localized prostate cancer diag-
nosed in 2004–2011 were identified and classified
according to D’Amico criteria. Initial treatment modality
was recorded as surgery, radiation therapy, expectant
management, or hormone therapy. Temporal trends were
assessed by Chi-square for trend.
Results Of 6,203 clinically localized prostate cancers
meeting inclusion criteria, 34, 30, and 28 % were low-,
intermediate-, and high-risk disease, respectively. For low-
risk disease, use of expectant management (17–42 %,
p\ 0.001) and surgery (29–39 %, p\ 0.001) increased,
while use of radiation therapy decreased (49–19 %,
p\ 0.001). For intermediate-risk disease, use of surgery
increased (24–50 %, p\ 0.001), while radiation decreased
(58–34 %, p\ 0.001). Hormonal therapy alone was rarely
used for low- and intermediate-risk disease. For high-risk
patients, surgery increased (38–47 %, p = 0.003) and ra-
diation decreased (41–38 %, p = 0.026), while hormonal
therapy and expectant management remained stable.
Discussion There are encouraging trends in the manage-
ment of clinically localized prostate cancer in New
Hampshire, including less aggressive treatment of low-risk
cancer and increasing surgical treatment of high-risk
disease.
Keywords Prostate cancer  Management trends  Risk
stratification  Active surveillance  Surgery
Introduction
Prostate cancer is the most common cancer diagnosis in
men in the USA, with *220,000 new diagnosis projected
in 2015. While most prostate cancer is slow-growing and
non-lethal, a subset of cancers will become metastatic and
cause mortality (*28,000 men in 2015) [1]. A newly di-
agnosed cancer is categorized as ‘‘low,’’ ‘‘intermediate,’’ or
‘‘high risk’’ based on biopsy findings, prostate-specific
antigen (PSA) level, and physical examination findings
(presence or absence of prostate nodularity) [2]. This risk
category reflects the likelihood of progression and lethality
and is used for making treatment decisions in conjunction
with patient age, health status, and other concerns such as
sexual and urinary function.
Longitudinal data have demonstrated a high rate of
treatment for all risk categories [3]. While aggressive
treatment in the form of surgery or radiation therapy is
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appropriate for more aggressive cancers, ‘‘low-risk’’ dis-
ease can often be safely observed, and patients can be
spared the side effects of treatment. There are emerging
data that ‘‘expectant management,’’ including active
surveillance (with follow-up biopsy) and watchful waiting
(with monitoring based on symptoms only), is safe and
associated with a low risk of cancer mortality for appro-
priate low-risk patients. In fact, a study with a follow-up
time of 18 years found that patients with low-risk cancer
were far more likely to die from causes other than prostate
cancer [4]. These approaches have been incorporated into
recent treatment guidelines by the American Urological
Association, European Association of Urology, and the
National Comprehensive Cancer Network [6–8].
Nonetheless, there continues to be a high rate of aggressive
treatment of low-risk cancer, incurring treatment morbidity
without a concomitant survival benefit [5].
‘‘High-risk’’ prostate cancer presents the opposite chal-
lenge—many patients are treated with non-curative thera-
pies such as testosterone suppression or ‘‘hormone
therapy,’’ when they might benefit from aggressive local
treatment with radiation or surgery [9, 10]. This has pre-
sented a quality of care concern [11]. Additionally, while
radiation therapy has been used more commonly for
treatment of high-risk disease, studies have demonstrated
similar long-term outcomes between radiation therapy and
radical prostatectomy, with a suggestion of a benefit from
surgery for selected patients [12, 13] Ultimately, there are
multiple treatment options for all risk categories, and thus
treatment decisions are often considered ‘‘preference-sen-
sitive’’ and emerge from a nuanced conversation between
provider and patient [14, 15].
In this paper, we examined trends in the management of
localized prostate cancer in New Hampshire using state
cancer registry data. We sought to evaluate whether sta-
tewide practices are consistent with our growing under-
standing of prostate cancer behavior and potential optimal
therapies (i.e., increasing use of expectant management for
low-risk cancer and definitive therapy for higher-risk
cancer).
Materials and methods
Clinically localized (non-metastatic) prostate cancers di-
agnosed from 2004 to 2011 were identified in the New
Hampshire State Cancer Registry (NHSCR). NHSCR is a
statewide, population-based cancer surveillance program
that collects incidence data on all cancer cases diagnosed
or treated in New Hampshire residents, including clinical
data such as stage, a preoperative Gleason grade on a
transrectal biopsy or a transurethral resection specimen,
PSA, and initial treatment. Clinically localized disease was
defined as AJCC 7th Edition T Stage 1–2. Cases were
excluded for the following reasons: cancer confirmation
only by death certificates, autopsy, or pathology or nursing
home records; patients diagnosed and treated by the
Veterans Health Adminstration due to restrictions in data
use; evidence of lymph node involvement, N1, or metas-
tasis, M1; unclassified D’Amico risk category due to
missing or unconfirmed preoperative data. The study pe-
riod was initiated in 2004 as this is the first year in which
complete data were recorded, including preoperative PSA,
clinical stage, and biopsy Gleason score. 2011 was the
most recent year with complete information.
Cancers were stratified according to D’Amico risk
categories. Men with PSA \10, biopsy Gleason score 6,
clinical stage T1c, and/or clinical stage T2a were classified
as low risk, men with PSA 10–20, biopsy Gleason score 7,
and/or clinical stage T2b as intermediate risk, and men
with PSA[20, biopsy Gleason score 8?, and/or clinical
stage T2c? as high risk [2]. The initial treatment was
recorded as surgical therapy, radiation (external beam ra-
diotherapy and/or brachytherapy), primary androgen de-
privation (ADT) therapy (men on ADT plus radiation were
counted as initial radiation therapy), or expectant man-
agement (no therapy recorded within 6 months). The data
from the cancer registry were not granular enough to dif-
ferentiate ‘‘active surveillance’’ (monitoring with follow-up
biopsy) from ‘‘watchful waiting’’ (symptomatic monitoring
only). Subsequent treatment was not recorded in our ana-
lysis as our goal was to study initial therapy rather than
adjuvant or salvage therapies. Men who underwent subse-
quent treatment by another modality were not excluded,
however.
Temporal trends were assessed by Chi-square for trend,
with a p value of \0.05 considered significant. This in-
vestigation was approved by the Dartmouth Committee for
the Protection of Human Subjects, and data use was ap-
proved by the New Hampshire Department of Public
Health Services.
Results
Of the 7,706 potentially eligible cases, 1,062 were ex-
cluded because the preoperative D’Amico risk category
could not be calculated due to a missing biopsy Gleason
score or an uncertain source (biopsy vs. surgical pathol-
ogy). A further 441 were excluded because the D’Amico
risk category was unknown due to other missing data. The
remaining 6,203 men had clinically localized prostate
cancer and met the inclusion criteria. Demographics are
shown in Table 1. The mean age was 65.7 ± 9.3 years.
There was an average annual increase in diagnosis of
2.2 %, matching population growth among men over the
924 Cancer Causes Control (2015) 26:923–929
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No. % No. % No. % No. %
Age 0.000
\50 84 3.6 33 1.7 34 1.8 151 2.4
50–65 1,249 54.3 910 45.6 780 41.0 2,939 47.4
66–75 808 35.1 768 38.5 703 36.9 2,279 36.7
[75 161 7.0 286 14.3 387 20.3 834 13.4
Mean, SD 63.6, 8.1 66.11, 8.4 67.4, 9.4 65.6, 8.8
Residencea 0.000
Rural 902 39.3 905 45.4 903 47.6 2,710 43.8
Urban 1,393 60.7 1,087 54.6 995 52.4 3,475 56.2
Marital status 0.000
Single 174 7.6 150 7.5 139 7.3 463 7.5
Married/common law 1,811 78.7 1,561 78.2 1,416 74.4 4,788 77.2
Divorced/separated 164 7.1 145 7.3 135 7.1 444 7.2
Widowed 76 3.3 84 4.2 116 6.1 276 4.4
Unknown 77 3.3 57 2.9 98 5.1 232 3.7
Calendar year 0.000
2004 239 10.4 143 7.2 256 13.4 642 10.4
2005 211 9.2 155 7.8 224 11.8 593 9.6
2006 256 11.1 214 10.7 239 12.6 710 11.4
2007 282 12.3 264 13.2 246 12.9 792 12.8
2008 310 13.5 307 15.4 233 12.2 848 13.7
2009 294 12.8 294 14.8 242 12.8 830 13.4
2010 370 16.0 290 14.5 235 12.3 893 14.4
2011 340 14.8 330 16.5 228 12.0 894 14.4
PSA lab value 0.000
\10 2,302 100.0 1,595 79.9 1,080 56.7 4,977 80.2
10 to\20 0 0.0 402 20.1 235 12.3 637 10.3
20? 0 0.0 0 0.0 498 26.2 498 8.0
Test ordered, result not in chart 0 0.0 0 0.0 5 0.3 5 0.1
Test not done 0 0.0 0 0.0 8 0.4 8 0.1
Unknown if done 0 0.0 0 0.0 78 4.1 78 1.3
Biopsy Gleason score 0.000
B6 2,302 100.0 234 11.7 478 25.1 3,014 48.6
7 0 0.0 1,763 88.3 551 28.9 2,314 37.3
8–10 0 0.0 0 0.0 864 45.4 864 13.9
No BX/TURP performed 0 0.0 0 0.0 4 0.2 4 0.1
Unknown if test done 0 0.0 0 0.0 7 0.4 7 0.1
AJCC cT 0.000
1 1,871 81.3 1,442 72.2 582 30.6 3,895 62.8
2a 254 11.0 255 12.8 100 5.3 609 9.8
2b 0 0.0 162 8.1 71 3.7 233 3.8
2c? 0 0.0 0 0.0 1,018 53.5 1,018 16.4
2NOS 177 7.7 138 6.9 104 5.5 419 6.8
Unknown 0 0.0 0 0.0 29 1.5 29 0.5
a 5 zip codes in New Hampshire have not been classified as either rural or urban, leading to a smaller n
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age of 65 in New Hampshire. There was a shift in the age
of diagnosed patients during the study period; 46 % of
patients were under 65 years of age in 2004 but 56 % in
2011. Similarly, 16 % of diagnosed men were older than
75 in 2004, but 11 % in 2011. Diagnoses were similarly
distributed within calendar years. Overall, 2,302 (34 %),
1,997 (30 %), and 1,904 (28 %) men were diagnosed with
low-, intermediate-, and high-risk disease, respectively.
There was a proportional decrease in high-risk disease
(39–27 % of all cancer diagnosis, p\ 0.001) and increase
in intermediate disease (26–36 %, p\ 0.001). Shifts in
low-risk cancer diagnosis did not reach significance.
Overall, there was an increase in use of surgery and ex-
pectant management as first treatment choice, and a de-
crease in radiation and primary androgen deprivation (see
Fig. 1), although patterns varied by D’Amico risk category.
Figure 2 depicts trends of initial treatments for patients
with low-risk disease. Use of expectant management more
than doubled (17–42 %) during the study period. Surgery
was also performed more often (29–39 %). The use of
initial radiation therapy decreased significantly (49–19 %),
as did treatment with initial androgen deprivation
(5–0.3 %).
For intermediate-risk patients, surgery rates doubled
(24–50 %), while radiation (58–34 %) and primary hor-
monal deprivation decreased (9–3 %) as shown in Fig. 3.
There was no statistically significant change in use of ex-
pectant management, which was used in 13 % of cases.
Among patients with high-risk disease, surgery and ra-
diation were each used as initial treatment in about 40 % of
the cases with fluctuations between years as shown in
Fig. 4. There was, however, a statistically significant trend
toward increased surgical treatment (38–47 %, p = 0.003)
and a decrease in radiation therapy (41–38 %, p = 0.026).
The changes in hormonal therapy and expectant manage-
ment did not display a statistically significant trend.
The median age of men in each treatment group was
60.4 ± 6.9 for surgery, 68.8 ± 7.2 for radiation,
68.9 ± 9.4 for expectant management, and 73.2 ± 8.6 for
initial hormonal therapy.
Discussion
Prostate cancer is a common disease that is generally non-
lethal; however, it can also behave aggressively leading to
metastasis and death. Initial ‘‘risk categorization’’ based on
laboratory, biopsy, and physical examination data reflects
the likelihood of an adverse outcome and helps to inform
decisions regarding treatment [1]. Surgery (radical prosta-
tectomy) and radiation therapy (external beam therapy and/
or radioactive seed therapy) are first-line interventions for
localized prostate cancer [6]. Notably, there have been no
prospective, randomized trials comparing surgery and ra-
diation in this setting; data regarding comparative effec-
tiveness are limited to retrospective, matched cohort trials
that cannot avoid selection bias [2, 16, 17]. Thus, absent
level 1 evidence favoring one therapy, decisions for those
pursuing treatment frequently depend on patient and pro-
vider preferences and resource availability [14, 15]. An
alternative strategy for management of localized cancer is
observation. This is particularly considered for low-risk
disease, as it has a low risk of progression, and patients will
generally die from another cause [18, 19]. As surgery and
radiation therapy have well-described morbidity (e.g.,
erectile, urinary, and/or bowel dysfunction), monitoring a
low-risk cancer is often a sensible approach to balance
risks and benefits, and to optimize quality of life [20]. Fi-
nally, hormone therapy alone, also called androgen depri-
vation therapy (ADT), is a treatment for metastatic cancer
that can reduce morbidity but has not been shown to im-
prove survival, and is considered inappropriate as singular
therapy in cases of localized disease [6–8].
We performed this study to evaluate trends in manage-
ment of localized prostate cancer in New Hampshire and to














Fig. 1 Changes in initial
treatment modality for clinically
localized prostate cancer by
calendar year. Trends are
statistically significant with a
p value\0.001 for all treatment
modalities
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of appropriate practice. We demonstrated several findings
that are encouraging regarding the quality of treatment.
Perhaps most importantly, we found that observation or an
‘‘expectant management’’ strategy has become increasingly
common as first-line treatment for low-risk disease. These
trends reflect emerging data from observational studies that
such strategies are safe and appropriate for most low-risk
patients [20]. A study by Weiner et al. [21] recently ex-
amined the utilization of non-curative initial management
in the Surveillance, Epidemiology and End Result Program
(SEER) and National Cancer Data Base (NCDB). These
authors also found a significant rise in expectant
management for low-risk cancer (SEER 20–31 %, NCDB
12–21 % from 2004 to 2010); however, the shift toward
this approach in New Hampshire was more dramatic
(18–42 % from 2004 to 2011). New Hampshire is largely a
rural state; however, there are regional referral centers
where most patients are treated. Thus, we postulate that
consolidation of care at certain centers has led to more
rapid uptake of expectant management for low-risk disease.
The New Hampshire State Cancer Registry collects the
same core set of variables as other national registries such
as SEER or NCDB, and it resembles SEER in that it pro-















Fig. 2 Changes in initial
treatment modality for D’Amico
low risk clinically localized
prostate cancer by calendar
year. Trends are statistically
significant with a p value
















Fig. 3 Changes in initial
treatment modality for D’Amico
intermediate risk clinically
localized prostate cancer by
calendar year. Trends are
statistically significant with a
















Fig. 4 Changes in initial
treatment modality for D’Amico
intermediate risk clinically
localized prostate cancer by
calendar year. Trends are
statistically significant with for
surgery (p = 0.003) and
radiation (p = 0.026)
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produce population-based statistics but collects data from
hospitals that are accredited by the American College of
Surgeons Commission on cancer.
Despite these encouraging trends, our data also
demonstrate that the overall treatment rate for low-risk
cancer is high ([50 % in 2011). While this likely reflects
continued overtreatment of many patients, it is notable that
selected cases of low-risk cancer should be treated ag-
gressively, e.g., patients with high-volume disease, family
history of early mortality from prostate cancer, and sig-
nificant anxiety associated with the monitoring process.
Additional studies are needed to determine whether pa-
tients with low-risk cancer are being appropriately selected
for treatment, and how to further encourage observational
strategies to reduce overtreatment.
Interestingly, our data demonstrate increasing use of
surgical treatment for low-risk cancer with a parallel de-
crease in radiation therapy. Reasons for this ‘‘exchange’’ of
interventions are unclear, though the advent of less inva-
sive forms of prostatectomy (i.e., robotic surgery), which
was introduced to New Hampshire during the study period,
may contribute. For intermediate-risk cancer, trends
demonstrate a similar rise in use of surgery with a decrease
in radiation therapy. For this risk category, treatment is
recommended for most patients, provided they do not have
a significantly shortened life expectancy, though there are
no strict guidelines favoring surgery or radiation therapy
[22]. The rise in use of surgical therapy likely reflects di-
verse factors that cannot be captured in this study, though
this is a ripe area of study to determine factors influencing
treatment decisions for these patients.
For high-risk cancer, we demonstrate a significant in-
crease in the use of surgical therapy, with a slight decrease
in use of radiation. While radiation therapy has been the
historical default treatment option for clinically localized
high-risk disease, surgical treatment has been increasingly
considered as a primary treatment. Data have emerged that
surgery may achieve cure with wide surgical resection and
pelvic lymph node removal, as well as a favorable outcome
when used in concert with adjuvant or salvage radiation
and hormone therapy [23]. In the contemporary treatment
arena, it is critical that surgery be discussed with and
contemplated by those with localized high-risk cancer, as it
may better meet patient preferences than primary radiation
therapy. Thus, it is encouraging that aggressive local
therapy with surgery alone, or as a starting point for a
multimodal approach, is being offered to patients with
high-risk cancer. Finally, we found a low, stable rate of
hormone monotherapy for high-risk cancer. This is en-
couraging, as hormone therapy lacks a survival benefit for
clinically localized disease, may have significant side ef-
fects, and has been shown to be overused in the treatment
of these patients [9, 10].
There are numerous variables that may affect treatment
choices for prostate cancer, including screening patterns
and stage migration. Studies have demonstrated a decrease
in rates of screening, particularly in older patients, after the
2008 United States Preventive Services Task Force rec-
ommendations [24]. While our data did not incorporate
screening practices, we did find no decrease in overall
cancer rates during the study period, though there were
some shifts in risk categories; specifically, more interme-
diate-risk and fewer higher-risk cancers were identified.
While these changes may impact overall treatment trends,
we report treatment decisions within risk categories which
make these changes less relevant. In terms of demographic
shifts, there were fewer diagnoses in older men during our
study period, however, this change was small and we do
not believe this significantly impacted treatment decisions.
There are some limitations of our study that warrant
discussion. The registry data did not contain comorbidity
data that might be used to assess competing risks of death
and how these might impact treatment practices. As such,
we were only able to capture trends in treatment without
assessing potential medical confounders. Also, while the
data collected by NHSCR are of high quality, 19.5 % of
eligible cases were excluded due to missing clinical data. It
is important, though, to interpret this number in light of our
strict inclusion criteria that required clinical stage, PSA,
and biopsy Gleason score for accurate categorization. We
could not assess differences in disease risk between in-
cluded and excluded patients because the latter, by
definition, had incomplete data.
Another limitation of our study is our definition of
‘‘expectant management’’ as those with no intervention
within 6 months of diagnosis. This is the conventional
definition used in the literature for population-based stud-
ies, though it may include some patients who had delayed
treatment but nonetheless had planned on a definitive in-
tervention, for instance, in the 6- to 12-month window.
Finally, our data represent practice within a largely rural
state and may not be generalizable to other regions. In
particular, travel distances and extreme winter weather
may influence treatment decisions, especially when multi-
ple trips for treatment would be required [25]. We are
currently evaluating the impact of distant to a radiation
facility on treatment decisions and hope to report this in a
future manuscript.
Conclusion
There are encouraging trends in the management of
clinically localized prostate cancer in New Hampshire, in-
cluding increased observation of low-risk cancer, and in-
creasing surgical treatment of high-risk disease. Continued
928 Cancer Causes Control (2015) 26:923–929
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efforts to study and refine practice patterns will enable us to
optimize our approaches to this heterogeneous disease.
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